GenSight Biologics Annual General Meeting on June 11, 2019
GenSight Biologics (Paris: SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on June 11, 2019 at 9:00 am CET at the company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris (France).
The notice containing the agenda and draft resolutions was published in the French BALO on May 6, 2019. The notice confirming the time and place of the meeting will be published in the French BALO and in a legal gazette on May 27, 2019.
The preparatory documents for the General Meeting listed in Article R. 225-73-1 of the French Commercial Code are posted on the company’s website (www.gensight-biologics.com) in the Investors, Documentation section.
The preparatory documents for the General Meeting will also be made available to shareholders as of the convening of the meeting. Thus, in accordance with applicable regulatory provisions:
- All registered shareholders may, until five days (included) before the meeting, request by email that the Company sends the documents referred to in Articles L. 225-115 and R. 225-83 of the French Commercial Code. For holders of bearer shares, the exercise of this right is subject to the provision of a certificate of participation in the bearer share accounts held by the authorized intermediary;
- Any shareholder may consult the documents referred to in Articles L. 225-115 and R. 225-83 of the French Commercial Code at the company’s headquarters.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics’ product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.